Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
TheFly reported on December 19 that BMRN announced it will acquire Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion, paying $14.50 per share. The deal strengthens BMRN's position in rare metabolic diseases by adding Amicus's two marketed therapies: Galafold for Fabry disease and the Pombiliti + Opfolda regimen for Pompe disease, which generated about $599 million in combined revenues over the past four quarters. The corporation expects the transaction to close in Q2 2026, be accretive to non-GAAP earnings per share within 12 months, and substantially accretive beginning in 2027. It also gains U.S. rights to DMX-200, a Phase 3 candidate for focal segmental glomerulosclerosis. Analysts largely praised the strategic fit. Leerink Partners, Oppenheimer, and Needham highlighted the deal's synergy with BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN)'s global infrastructure and enzyme therapy focus, and its potential to boost sales and long-term growth. Con
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.MarketBeat
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating. They now have a $14.50 price target on the stock.MarketBeat
- Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Citigroup Inc.. They now have a $14.50 price target on the stock, down previously from $17.00.MarketBeat
- Assessing Amicus Therapeutics Valuation After a 48.3% One Month Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger [Yahoo! Finance]Yahoo! Finance
FOLD
Earnings
- 11/4/25 - Beat
FOLD
Sec Filings
- 12/19/25 - Form 144
- 12/19/25 - Form DEFA14A
- 12/19/25 - Form 8-K
- FOLD's page on the SEC website